Healthcare Industry News:  radiosurgery 

Devices Oncology Regulatory

 News Release - December 18, 2014

Elekta Flexitron brachytherapy treatment delivery available in China

China Food and Drug Administration (CFDA) approves cancer treatment system

BEIJING, Dec. 18, 2014 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) announces that the China Food and Drug Administration (CFDA) has approved Elekta's Flexitron® brachytherapy afterloading platform for sale and marketing in China.

In China there is a high prevalence of gynecologic cancers, as well lung, breast, colorectum and esophagus cancers. Many patients with such cancers can be effectively treated with brachytherapy. With the introduction of Flexitron®, hundreds of thousands of cancer patients can benefit from being treated with this new, advanced afterloading platform.

For hospitals offering brachytherapy, Flexitron® can reduce workflow complexity and improve efficiency. It is revolutionizing safety and workflow in the modern brachytherapy practice. By being designed around an upgradable architecture, Flexitron represents a truly safe investment for the future.

Anming Gong, Elekta's Managing Director for China, says: "Elekta is happy to introduce to China an effective brachytherapy solution – especially for gynecologic cancers. The timing is perfect as recently published guidelines from the 2014 CSTRO/SANTRO Symposium in October state that brachytherapy is a key technique for cervical cancer treatment and is instrumental in improving the control and survival rates of women with these cancers."

There are about 130,000 new cervical cancer patients per year in China and about 40,000 Chinese patients are treated with brachytherapy annually.

Elekta offers complete brachytherapy solutions, including afterloading platforms, applicators and treatment planning. For Asian patients in particular, Elekta has developed dedicated small applicators designed to fit their anatomy.

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Kris Walmsley, Corporate Communications Manager, Elekta AB
Tel: +46 70 537 9545, e-mail: kris.walmsley@elekta.com
Time zone: CET: Central European Time

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.


Source: Elekta

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.